SR ONE CAPITAL MANAGEMENT, LP Q1 2025 Filing
Filed May 13, 2025
Portfolio Value
$389.3B
Holdings
12
Report Date
Q1 2025
Filing Type
13F-HR
All Holdings (12 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACLXArcellx, Inc. | 2,346,630 | $153.9B | 39.54% | |
| 2 | SPRYARS Pharmaceuticals, Inc. | 4,012,903 | $50.5B | 12.97% | |
| 3 | MLYSMineralys Therapeutics Inc. | 3,127,933 | $49.7B | 12.76% | |
| 4 | ZBIOZenas BioPharma, Inc | 4,911,539 | $38.8B | 9.97% | |
| 5 | CRSPCRISPR Therapeutics AG | 1,048,951 | $35.7B | 9.17% | |
| 6 | DSGNDesign Therapeutics, Inc. | 6,526,476 | $25.2B | 6.47% | |
| 7 | ALMSAlumis Inc. | 1,959,896 | $12.0B | 3.09% | |
| 8 | OCSOculis Holding AG | 322,500 | $6.1B | 1.58% | |
| 9 | NKTXNkarta, Inc. | 3,333,333 | $6.1B | 1.58% | |
| 10 | ORKAOruka Therapeutics, Inc | 430,330 | $4.4B | 1.13% | |
| 11 | KALAKALA Bio, Inc. | 598,940 | $3.4B | 0.88% | |
| 12 | ENGNenGene Holdings Inc. | 747,750 | $3.3B | 0.86% |